Investment case
Takeda Pharmaceutical Company Limited
TAK · 2 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 2 macro, policy, and market developments to Takeda Pharmaceutical Company Limited since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for TAK yet, so no modelled value is shown. The TAK valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run TAK on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide
Potential future competition in the hypoparathyroidism market, particularly given their past involvement.
· Moves market share for existing hypoparathyroidism treatments, pricing power for existing therapies
What changed, by assumption
- 2026-08-27MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide
- 2026-09-29Keros Therapeutics to Distribute 25% of $20 Million Takeda Milestone to Stockholders
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Keros Therapeutics to Distribute 25% of $20 Million Takeda Milestone to Stockholders | watch | 3-12m | 0.10 |
| 2026-08-27 | MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide | watch | 1-5y | 0.40 |